Update on the Classification and Management of Cutaneous Lupus Erythematosus
Abstract
Lupus erythematosus (LE) is an immune-mediated, chronic, complex disease that can affect anyone. It occurs most commonly in middle-aged women; however, it can also affect men, and individuals of all ages. The skin is one of the most commonly affected organs in systemic lupus erythematosus (SLE). Cutaneous involvement and skin manifestations are known to occur in 60% to 85% of patients over the course of the disease. Skin manifestations are the first type of presentation in virtually 20%-25% of patients.
References
Vale ECSD, Garcia LC. Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects. Anais Brasileiros de Dermatologia. 2023 Mar 1. doi: 10.1016/j.abd.2022.09.005. Epub ahead of print. PMID: 36868923.
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis & Rheumatism. 2012 Aug;64(8):2677-86.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis & Rheumatology. 2019 Sep;71(9):1400-12. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. PMID: 31383717.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and rheumatism. 1997 Sep 1;40(9):1725. doi: 10.1002/art.1780400928. PMID: 9324032.
Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4:471-5.
Gilliam JN, Sontheimer RD. Skin manifestations of SLE. Clin Rheum Dis 1982;8:207-18.
Stull C, Sprow G, Werth VP. Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist. The Journal of Rheumatology. 2023 Jan 1;50(1):27-35. doi: 10.3899/jrheum.220089. Epub 2022 Sep 15. PMID: 36109075.
Jessop S, Whitelaw DA, Grainge MJ, Jayasekera P. Drugs for discoid lupus erythematosus, Cochrane Database Syst. Rev. 5 (2017) CD002954. https://doi. org/10.1002/14651858.CD002954.pub3.
Roenigk Jr HH, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis. 1980 Mar;25(3):281-5.
Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clinical and Experimental Dermatology. 2009 Oct 1;34(7):776-80. https://doi.org/10.1111/j.1365-2230.2008.03138.x.
Pothinamthong P, Janjumratsang P. A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. Journal of the Medical Association of Thailand. 2012 Jul 1;95(7):933.
Kuhn A, Gensch K, Haust M, Schneider SW, Bonsmann G, Gaebelein-Wissing N, Lehmann P, Wons A, Reitmeir P, Ruland V, Luger TA. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. Journal of the American Academy of Dermatology. 2011 Jul 1;65(1):54-64. https://doi.org/10.1016/j.jaad.2010.03.037, 64 e51-52.
Wang X, Zhang L, Luo J, Wu Z, Mei Y, Wang Y, Li X, Wang W, Zhou H. Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: a randomized, controlled clinical trial. The Journal of Clinical Pharmacology. 2015 Nov;55(11):1221-8. https://doi. org/10.1002/jcph.537.
Edwards KR, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. Journal of the American Academy of Dermatology. 1999 Dec 1;41(6):1049-50. https://doi.org/10.1016/s0190-9622(99)70278-1.
Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Cutis. 1991 May;47(5):351-5.
Terao M, Matsui S, Katayama I. Two cases of refractory discoid lupus erythematosus successfully treated with topical tocoretinate. Dermatology Online Journal. 2011 Apr 1;17(4).
Park JJ, Little AJ, Vesely MD. Treatment of cutaneous lupus with topical ruxolitinib cream. JAAD Case Reports. 2022 Oct 1;28:133-5. doi: 10.1016/j.jdcr.2022.08.038. PMID: 36159722; PMCID: PMC9494033.
Wenzel J, van Holt N, Maier J, Vonnahme M, Bieber T, Wolf D. JAK1/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. The Journal of Investigative Dermatology. 2016 Feb 23;136(6):1281-3. doi: 10.1016/j.jid.2016.02.015. Epub 2016 Feb 23. PMID: 26916391.
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8.
N. Yokogawa, H. Eto, A. Tanikawa, et al. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial, Arthritis Rheum. 69 (2017) 791–799. https:// doi.org/10.1002/art.40018.
Kirou KA, Lee C, George S, Louca K, Peterson MGE, Crow MK: Activation of the Interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005 May;52(5):1491–1503.
Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on toll-like receptors? Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2006 Oct;54(10):3068-70.
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016 Jun 1;123(6):1386-94. doi:10.1016/j.ophtha.2016.01.058.
Lu Q, Long H, Chow S, Hidayat S, Danarti R, Listiawan Y, Deng D, Guo Q, Fang H, Tao J, Zhao M. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. Journal of Autoimmunity. 2021 Sep 1;123:102707.
Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatric Rheumatology. 2009 Dec;7:1-9.
Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, Frassi M, Biasini C, Zatti S, Chirico G. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. Journal of Perinatology. 2005 Feb;25(2):86-9.
Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G, Kuhn A. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmunity Reviews. 2013 Jan 1;12(3):444-54. doi: 10.1016/j.autrev.2012.08.019. Epub 2012 Sep 18. PMID: 23000206.
O’Kane D, McCourt C, Meggitt S, D’Cruz DP, Orteu CH, Benton E, Wahie S, Utton S, Hashme M, Mohd Mustapa MF, Exton LS. British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021. British Journal of Dermatology. 2021 Dec;185(6):1112-23.
Presto JK, Werth VP. Cutaneous lupus erythematosus: current treatment options. Current Treatment Options in Rheumatology. 2016 Mar;2:36-48. https://doi.org/10.1007/s40674-016-0033-z.
Kuhn A, Aberer E, Bata-Csörgő Z, Caproni M, Dreher A, Frances C, Gläser R, Klötgen HW, Landmann A, Marinovic B, Nyberg F. S2k guideline for treatment of cutaneous lupus erythematosus–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology. 2017 Mar;31(3):389-404.
Wenzel J, Brähler S, Bauer R, Bieber T, Tüting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. British Journal of Dermatology. 2005 Jul 1;153(1):157-62.
Islam MN, Hossain M, Haq SA, Alam MN, Ten Klooster PM, Rasker JJ. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. International Journal of Rheumatic Diseases. 2012 Feb;15(1):62-8.
Fruchter R, Kurtzman DJ, Patel M, Merola J, Franks AG, Vleugels RA, Femia AN. Characteristics and alternative treatment outcomes of antimalarial-refractory cutaneous lupus erythematosus. JAMA Dermatology. 2017 Sep 1;153(9):937-9.
Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatology International. 1998 Aug;18:59-62.
Wang D, Chen H, Wang S, Zou Y, Li J, Pan J, Wang X, Ren T, Zhang Y, Chen Z, Feng X. Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China. Clinical Rheumatology. 2016 Jun;35:1521-7. doi: 10.1007/s10067-016-3256-3.
Frankel HC, Sharon VR, Vleugels RA, Merola JF, Qureshi AA. Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. International Journal of Dermatology. 2013 Nov 1;52(11):1407-9. doi: 10.1111/j.1365-4632.2011.05200.x.
Moura Filho JP, Peixoto RL, Martins LG, Melo SD, Carvalho LL, Pereira AK, Freire EA. Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. Anais Brasileiros de Dermatologia. 2014 Jan;89:118-25. doi: 10.1590/abd1806-4841.20142146.
Domingo S, Solé C, Moliné T, Ferrer B, Ordi-Ros J, Cortés-Hernández J. Efficacy of thalidomide in discoid lupus erythematosus: insights into the molecular mechanisms. Dermatology. 2020;236(5):467-76.
Cesbron E, Bessis D, Jachiet M, Lipsker D, Cordel N, Bouaziz JD, Bagot M, Arnaud L, Barbaud A, Francès C, Chasset F. Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: a multicenter retrospective study. Journal of the American Academy of Dermatology. 2018 Jul 1;79(1):162-5.
Yuki EF, Soares R, Kupa LD, Heise CO, Aikawa NE, Arnone M, Romiti R, Pedrosa TD, Silva CA, Bonfa E, Pasoto SG. One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. Lupus. 2021 May;30(6):956-64.
Curtiss P, Liebman T, Khorolsky C, Brinster N, Beasley J, Sicco KL. Systemic lupus erythematosus and antineutrophil cytoplasmic antibody–associated vasculitis: an emerging overlap syndrome with cutaneous manifestations. JAAD Case Reports. 2018 Jun 1;4(5):493-6.
de Risi-Pugliese T, Aubart FC, Haroche J, Moguelet P, Grootenboer-Mignot S, Mathian A, Ingen-Housz-Oro S, Hie M, Wendremaire N, Aucouturier F, Lepelletier F. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases. In Seminars in Arthritis and Rheumatism 2018 Aug 1 (Vol. 48, No. 1, pp. 83-89). WB Saunders.
Zampeli E, Moutsopoulos HM. Dapsone: an old drug effective for subacute cutaneous lupus erythematosus. Rheumatology. 2019 May 1;58(5):920-1.
Garza-Mayers AC, McClurkin M, Smith GP. Review of treatment for discoid lupus erythematosus. Dermatologic Therapy. 2016 Jul;29(4):274-83.
Ujiie H, Shimizu T, Ito M, Arita K, Shimizu H. Lupus erythematosus profundus successfully treated with dapsone: review of the literature. Archives of Dermatology. 2006 Mar 1;142(3):393-403.
Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatology. 1986;172(4):214-7.
Klebes M, Wutte N, Aberer E. Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature. Dermatology. 2016;232(1):91-6.
D’Erme AM, Milanesi N, Difonzo EM, Lotti T, Gola M. Treatment of refractory subacute cutaneous lupus erythematosus with oral isotretinoin: a valid therapeutic option. Dermatol Ther. 2012;25:281-2. 10.1111/j.1529-8019.2012.01461.x
Al-Mutairi N, Rijhwani M, Nour-Eldin O. Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy. The Journal of Dermatology. 2005 Jun;32(6):482-6.
Laosakul K, Chiewchanvit S, Chuamanochan M, Tovanabutra N. Acitretin treatment in antimalarial-refractory/intolerant discoid lupus erythematosus: A prospective, open-label, uncontrolled study. Lupus. 2022 Apr;31(5):575-81.
Kuhn A, Patsinakidis N, Luger T. Alitretinoin for cutaneous lupus erythematosus. Journal of the American Academy of Dermatology. 2012 Sep 1;67(3):e123-6.
Verdelli A, Corrà A, Mariotti EB, Aimo C, Ruffo di Calabria V, Volpi W, Quintarelli L, Caproni M. An update on the management of refractory cutaneous lupus erythematosus. Front Med (Lausanne). 2022 Sep 23;9:941003. doi: 10.3389/fmed.2022.941003. PMID: 36213629; PMCID: PMC9537468.
Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nature Reviews Rheumatology. 2019 Sep;15(9):519-32.
Kuhn A, Landmann A, Wenzel J. Advances in the treatment of cutaneous lupus erythematosus. Lupus. 2016 Jul;25(8):830-7. doi: 10.1177/0961203316641771.
